Bharat Biotech’s intranasal COVID-19 vaccine gets DCGI approval for restricted use | The Financial Express

Bharat Biotech’s intranasal COVID-19 vaccine gets DCGI approval for restricted use

This vaccine candidate was evaluated in phase I, II and III clinical trials with successful results, a press release from the city-based vaccine-maker said.

Bharat Biotech’s intranasal COVID-19 vaccine gets DCGI approval for restricted use
iNCOVACC is a recombinant replication deficient adenovirus vectored vaccine with a pre-fusion stabilised spike protein. (File Photo: IE)

Bharat Biotech International Limited (BBIL) on Tuesday announced that its iNCOVACC (BBV154), world’s first intranasal COVID-19 vaccine has received approval from Drugs Controller General of India under Restricted Use in Emergency Situation for ages 18 and above.

Also Read | Clinical data disclosure critical for Bharat Biotech COVID-19 intranasal vaccine success in India: GlobalData

iNCOVACC is a recombinant replication deficient adenovirus vectored vaccine with a pre-fusion stabilised spike protein. This vaccine candidate was evaluated in phase I, II and III clinical trials with successful results, a press release from the city-based vaccine-maker said.

Clinical trials were conducted to evaluate iNCOVACC as a primary dose schedule, as heterologous booster dose for subjects who have previously received two doses of the two commonly administered Covid vaccines in India.

Also Read | Intranasally delivered Sputnik V shows ‘durable’ immune response against COVID-19 in animals: Study

Krishna Ella, Chairman and Managing Director, Bharat Biotech, said, “We are proud to announce the approval of iNCOVACC, a global game changer in intranasal vaccines technology and delivery systems. Despite the lack of demand for COVID-19 vaccines, we continued product development in intra-nasal vaccines to ensure that we are well prepared with platform technologies for future infectious diseases.” Phase III trials of the vaccine were conducted for safety, immunogenicity in about 3,100 subjects, in 14 trial sites across India, Bharat Biotech said.

Get live Share Market updates and latest India News and business news on Financial Express. Download Financial Express App for latest business news.